A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics of Sulfatinib in Advanced Solid Tumors

Trial Profile

A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics of Sulfatinib in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 23 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 02 Aug 2016 According to a Chi-Med media release, the company expects to initiate a U.S. Phase II (see profile 2629090) in 2017 based on the conclusion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top